Cite
HARVARD Citation
Elmeliegy, M. et al. (2020). Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. Journal of clinical pharmacology. pp. 1334-1343. [Online].